Printed From:

Lantus® Provides Proven HbA1c Control

The long-term landmark ORIGIN trial1

ORIGIN = Outcome Reduction with Initial Glargine Intervention

Study Design

A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per discretion of the investigator. Median follow-up: 6.2 years.1,2

No statistically significant differences between Lantus® and standard care in the co-primary endpoints. Similar results were observed between Lantus® and standard care for all-cause mortality.

From Lantus Prescribing Information.1
View Lantus® long-term CV safety data from the ORIGINS trial.
FPG = fasting plasma glucose; IFG = impaired fasting glucose; IGT = impaired glucose tolerance


  1. Lantus Prescribing Information. August 2015.
  2. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al., ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    N Engl J Med. 2012 Jul 26;367(4):319-28.
    doi: 10.1056/NEJMoa1203858.
    Epub 2012 Jun 11.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. August 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. August 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.